Non-Current Assets
PP&E (Net)
Alnylam Pharmaceuticals PP&E (Net) increased by 1.0% to $518.26M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 3.9%, from $498.68M to $518.26M. Over 5 years (FY 2020 to FY 2025), PP&E (Net) shows an upward trend with a 2.0% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ3 2015
Last reportedQ4 2025
How to read this metric
An increase indicates investment in future capacity or infrastructure, while a decrease suggests asset aging or a shift toward an asset-light model.
Detailed definition
The book value of long-term physical assets such as manufacturing facilities, data centers, and retail stores, net of ac...
Peer comparison
Varies significantly based on whether a company owns its manufacturing plants or outsources production to third-party partners.
Metric ID:
property_plant_equipment_netHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $470.70M | $484.94M | $501.96M | $504.39M | $508.20M | $514.82M | $523.49M | $523.03M | $527.47M | $525.59M | $526.06M | $523.46M | $517.16M | $507.00M | $502.78M | $498.68M | $499.79M | $501.75M | $513.15M | $518.26M |
| QoQ Change | — | +3.0% | +3.5% | +0.5% | +0.8% | +1.3% | +1.7% | -0.1% | +0.8% | -0.4% | +0.1% | -0.5% | -1.2% | -2.0% | -0.8% | -0.8% | +0.2% | +0.4% | +2.3% | +1.0% |
| YoY Change | — | — | — | — | +8.0% | +6.2% | +4.3% | +3.7% | +3.8% | +2.1% | +0.5% | +0.1% | -2.0% | -3.5% | -4.4% | -4.7% | -3.4% | -1.0% | +2.1% | +3.9% |
Range$470.70M – $527.47M
CAGR+2.0%
Avg YoY Growth+1.0%
Median YoY Growth+1.3%
Current Streak4 quarters growth
PP&E (Net) at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's pp&e (net)?
- Alnylam Pharmaceuticals (ALNY) reported pp&e (net) of $518.26M in Q1 2026.
- How has Alnylam Pharmaceuticals's pp&e (net) changed year-over-year?
- Alnylam Pharmaceuticals's pp&e (net) increased by 3.9% year-over-year, from $498.68M to $518.26M.
- What is the long-term trend for Alnylam Pharmaceuticals's pp&e (net)?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's pp&e (net) has grown at a 2.0% compound annual growth rate (CAGR), from $465.03M to $513.15M.
- What does pp&e (net) mean?
- The value of the company's physical buildings, machinery, and equipment after accounting for wear and tear.